Cancer Susceptibility and the Functions of BRCA1 and BRCA2  by Venkitaraman, Ashok R.
Cell, Vol. 108, 171–182, January 25, 2002, Copyright 2002 by Cell Press
ReviewCancer Susceptibility
and the Functions
of BRCA1 and BRCA2
channels tumor evolution down particular routes. Evolv-
ing evidence concerning the participation of BRCA pro-
teins in other cellular processes will also be analyzed,
emphasizing the many significant challenges in our cur-
rent understanding of cancer predisposition induced by
Ashok R. Venkitaraman1
University of Cambridge
CRC Department of Oncology and The Medical
Research Council Cancer Cell Unit
Hutchison/MRC Research Centre
Hills Road BRCA gene disruption.
Cambridge CB2 2XZ
United Kingdom Breast Cancer Genetics
The genetic susceptibility to breast cancer caused by
mutations in BRCA1 or BRCA2 is just one piece of a
Inherited mutations in BRCA1 or BRCA2 predispose to larger picture (reviewed in Nathanson et al., 2001). About
breast, ovarian, and other cancers. Their ubiquitously 10% of breast cancer cases cluster in families; some
expressed protein products are implicated in pro- are due to highly penetrant germline mutations in one
cesses fundamental to all cells, including DNA repair or another of a small number of genes, such as BRCA1 or
and recombination, checkpoint control of cell cycle, BRCA2, giving rise to high cancer risk. But the majority of
and transcription. Here, I examine what is known about cases (“sporadic”) exhibit no clear-cut familial clustering
the biological functions of the BRCA proteins and ask and probably result from the collective effect of multiple,
how their disruption can induce susceptibility to spe- poorly penetrant variations in a much larger group of
cific types of cancer. genes, modified by environmental factors. Of familial
cases, germline mutations in BRCA1 or BRCA2 account
for between 15% and 20% of the observed risk (but are
Questions concerning the biological functions of the found in over 80% of families where six or more cases
proteins encoded by the breast cancer susceptibility occur). Only a small fraction of the remaining risk can
genes have dominated the field since the genes were currently be attributed to germline mutations in other
identified some six years ago through the analysis of known genes (for example, the p53 tumor suppressor,
families at high risk from breast and ovarian cancer. the STK11/LKB1 protein kinase, or the PTEN phospha-
BRCA1 and BRCA2 encode very large proteins (Figure tase). Additional susceptibility alleles for familial breast
1), widely expressed in different tissues during the S cancer must therefore exist, but they have so far proven
and G2 phases, which localize to the cell nucleus. They difficult to identify (Easton, 1999).
bear little resemblance to one another or to proteins of One defective copy of BRCA1 or BRCA2 in the germ-
known function. Orthologs are not found in the yeast, line is enough to cause cancer predisposition, but the
fly, or worm genomes. Thus, BRCA1 and BRCA2 are second allele is consistently lost in tumor cells isolated
relative latecomers in evolution, belying their apparently from predisposed individuals. Thus, BRCA genes con-
fundamental role in mammalian cells, and hinting at spe- form at least in part to the classic paradigm for tumor
cialized, possibly tissue-specific, functions. These un- suppressor genes. On the other hand, somatic BRCA
usual features have at once confounded analyses of the mutations rarely occur in sporadic cancer cases.
biological function of the BRCA proteins, yet have also
enhanced their perceived value to the cancer biology field. Caretakers of Chromosomal Stability
Two major themes have emerged in the recent literature. Cancer susceptibility gene mutations fall into two gen-
First, both BRCA1 and BRCA2 work to preserve chromo- eral classes (Kinzler and Vogelstein, 1997). Genes whose
some structure, yet the precise nature of their contribu- mutation or altered expression relieves normal controls
tion has proven difficult to define, because both proteins on cell division, death, or lifespan, promoting the out-
have been implicated in a multitude of different processes growth of cancer cells, have been termed “gatekeep-
including DNA repair and recombination, cell cycle control, ers.” Those whose disruption causes genome instability,
and transcription. Second, the similarities between the increasing the frequency of alterations in gatekeeper
phenotypes induced by disruption of BRCA1 or BRCA2 genes, work instead as “caretakers.”
and their claimed cohabitation in certain macromolecu- A starting point from which to unravel the functions
lar complexes has prompted speculation that they work of BRCA1 and BRCA2 relevant to cancer predisposition
together in common cellular pathways. comes from the observation that cells deficient in the
In this review, I will analyze available information about murine BRCA2 homolog sustain spontaneous aberra-
the biological functions of the BRCA proteins and argue tions in chromosome structure (Figures 2A–2D) that ac-
that their role in the maintenance of chromosome struc- cumulate during division in culture (Patel et al., 1998).
ture stems from distinct rather than identical functions Microscopically, the abnormalities not only include bro-
in the biological response to DNA damage. A case will ken chromosomes and chromatids, but also triradial
be made that spontaneous chromosomal instability in and quadriradial structures, markers of defective mitotic
BRCA-deficient cells underpins their propensity to un- recombination that are typical of the human diseases
dergo neoplastic transformation and at the same time Bloom’s syndrome and Fanconi’s anemia, also associ-
ated with increased susceptibility to cancer (including
breast cancer). Spectral karyotyping (a chromosome1 Correspondence: arv22@cam.ac.uk
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Figure 1. Features of the Human BRCA
Proteins
BRCA1 contains an N-terminal RING domain,
nuclear localization signals (NLSs), and two
C-terminal BRCT domains of 110 residues
(also found in several proteins with functions
in DNA repair or cell cycle control). Interacting
proteins discussed in the text are shown be-
low approximate regions of binding. BRCA2
contains eight repeats of the 40 residue
BRC motifs. Six of the eight motifs in human
BRCA2 can bind directly to RAD51 when ex-
pressed in vitro.
“painting” technique) reveals gross chromosomal re- chromosome structure, suggesting that, in their role as
tumor suppressors, they behave as caretakers, sup-arrangements (GCRs) such as translocations or dele-
tions, as well as fusions that encompass multiple, non- pressing genome instability.
homologous chromosomes (Yu et al., 2000). Similar
structural aberrations occur in BRCA1-deficient mouse Chromosomal Instability through Inappropriate
DNA Double-Strand Break Repaircells (Xu et al., 1999a), as well as in BRCA1- or BRCA2-
deficient human cancer cells (Tirkkonen et al., 1997; Studies on yeast mutants that spontaneously accumu-
late GCRs implicate malfunctions in DNA repair or re-Gretarsdottir et al., 1998). Collectively, these findings
establish that BRCA genes are essential for preserving combination pathways (Chen et al., 1998a; Chen and
Figure 2. Chromosomal Instability through Inappropriate DNA Double-Strand Break Repair
(A–D) Spontaneous chromosomal instability in BRCA2-deficient murine cells. A typical metaphase spread is shown in the largest panel, with
aberrations in the U shaped normal mouse chromosomes enlarged on the right. Abbreviations are as follows: Ctb, chromatid break; Tr, triradial;
and Qr, quadriradial. Reproduced from Patel et al. (1998) with the permission of Cell Press.
(E) DSB repair in BRCA-deficient cells is routed down error-prone pathways because the preferred pathway, error-free HR, is not functional.
BRCA1 deficiency may also compromise SSA.
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Kolodner, 1999; Kraus et al., 2001). It emerges from routing of DSB processing down inappropriate pathways,
this work that double-strand DNA breaks (DSBs) are an rather than the failure of repair per se.
important precursor lesion for GCR formation and may A case can be made from recent data that this com-
arise when DSBs are repaired in an inappropriate way. mon defect in DSB “traffic control” nevertheless arises
In mammalian cells (Figure 2E), DSBs can be repaired from distinct roles for BRCA1 or BRCA2 in the mecha-
(reviewed in Karran, 2000; Khanna and Jackson, 2001; nisms for DSB repair. The differences are best viewed
van Gent et al., 2001) by nonhomologous end joining from the standpoint of relevant protein-protein interac-
(NHEJ), potentially an error-prone process in which nu- tions. In the discussion that follows, it will be proposed
cleotide alterations are tolerated at the sites of rejoin- that the major role of BRCA2 in DSB repair is through
ing, or by recombination between homologous DNA se- control of the RAD51 recombinase, while BRCA1 per-
quences (HR), error-free when the exchange is between forms a distinct and more general function as a link
identical sister chromatids (or homologous chromosomes). between the sensing/signaling and effector components
A third mechanism, single-strand annealing (SSA), is also of the mammalian response to DNA damage, helping to
initiated by homologous pairing, except that—unlike ensure that the ensuing response is appropriate to the
HR—the homology is between short stretches of single- initiating lesion.
stranded DNA (ssDNA) at staggered DSBs, and pairing
precedes religation, not strand exchange. SSA is error- BRCA2 Controls the RAD51 Recombinase
prone because sequence information can be lost or re- BRCA2 binds directly with RAD51 (Sharan et al., 1997;
arranged when ends overlapping by as little as 30 bp Wong et al., 1997), a eukaryotic homolog of bacterial
are unsuitably joined. RecA essential for DSB repair by HR (but not SSA). The
Mammalian experimental models reveal a complex interaction involves a substantial proportion of the total
relationship between DSB repair mechanisms and chro- cellular pool of each protein. It occurs primarily through
mosome stability (Khanna and Jackson, 2001; van Gent the40 amino acid BRC motifs in BRCA2, eight repeats
et al., 2001). On the one hand, error-prone DSB repair of which (Figure 1) are well conserved in sequence and
can provoke GCR formation. Deletions or translocations spacing from mammals to birds (Takata et al., 2002).
may result, for example, when broken ends from differ- RAD51 has a catalytic activity central to HR. It coats
ent chromosomes or nonadjacent regions of the same ssDNA to form a nucleoprotein filament that invades and
chromosome are promiscuously fused together by pairs with a homologous DNA duplex, initiating strand
NHEJ or SSA. On the other hand, deficiency of NHEJ exchange between the paired DNA molecules. Recent
can itself cause chromosomal instability, showing that evidence suggests that BRCA2 works directly to regu-
there are circumstances in which error-free HR alone late the availability and activity of RAD51 in this key
is insufficient. Thus, different mechanisms are used in reaction, consistent with the high stoichiometry of their
mammalian cells to deal with DSBs in different situa- binding (Figure 3).
tions, and failure to choose the right repair mechanism This model is based on the observation that formation
can promote—rather than prevent—chromosomal in- of the RAD51 nucleoprotein filament in vitro is efficiently
stability.
blocked by peptides encoding any one of several BRC
The mitotic cell cycle is one important determinant in
repeats (Davies et al., 2001), the RAD51 binding motifs
this choice. Repair by HR predominates during S/G2
within BRCA2. Inhibition is evident at a molar ratio of
phases of the mitotic cell cycle, when sister chromatids,
about 3:1 (BRC peptide:RAD51) and is equally effectivethe preferred substrate for error-free exchange, are
on preformed RAD51 nucleoprotein filaments. When inpresent. The proteins that carry out NHEJ are also pres-
the presence of BRC peptides, recombinant RAD51—ent at this time and can contribute to DSB repair, but
which normally polymerizes spontaneously—is ren-very little is known about how a choice can be made
dered largely monomeric. By analogy to RecA, polymer-between these mechanisms (Haber, 1999).
ization may be required for nucleoprotein filamentEvidence is emerging that GCRs in BRCA-deficient
formation, and its inhibition suggests a mechanismcells result from inappropriate DSB repair during S and
whereby BRC repeat binding could suppress RAD51G2 (Figure 2E), the phases when the BRCA proteins are
activity.maximally expressed. Recent work from several groups
Whether or not these in vitro biochemical observa-(Moynahan et al., 1999, 2001; Snouwaert et al., 1999;
tions based on BRC peptides are relevant to the cellularTutt et al., 2001; Xia et al., 2001) shows that BRCA1-
functions of full-length BRCA2 is yet to be tested. It isor BRCA2-deficient rodent cells or human tumors are
attractive to speculate that sequestration by BRCA2 ofspecifically deficient in HR, whereas, when measured,
RAD51—an avid, abundant DNA binding protein—mayNHEJ (and sometimes SSA) remains intact. This gives
be necessary to prevent the unwelcome activation ofrise to a scenario wherein spontaneous or induced DSBs
DNA recombination during normal DNA metabolismin BRCA-deficient cells are rerouted for repair by mecha-
(Figure 3). If correct, this predicts that the release ofnisms that are potentially error-prone, because the pre-
RAD51 from its sequestered, inactive state must specifi-ferred mode of (error-free) processing by HR is unavail-
cally be triggered by DNA damage or replication arrest.able. Experimental confirmation that error-prone DSB
Conceivably, the trigger could be phosphorylation ofrepair mechanisms predominate in murine BRCA2-defi-
BRCA2 or RAD51 by one of the protein kinase cascadescient cells has recently been published (Tutt et al., 2001),
known to signal these problems.and there is some evidence that this also occurs in BRCA1
Release from sequestration as meant here need notdeficiency (Moynahan et al., 1999; Snouwaert et al., 1999).
imply release from BRCA2 binding; it is also possibleThus, in its simplest conception, chromosomal instability
provoked by BRCA deficiency is the result of incorrect that BRCA2 carries active RAD51 to sites of DSB pro-
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Figure 3. Hypothetical Model for BRCA2
Function in HR
An outline of the HR mechanism is shown:
DNA damage or replication arrest cause
DSBs that activate signaling mechanisms (1)
and are then resected (2) by exonuclease ac-
tivity to generate ssDNA tracts. RAD51 is
loaded onto the ssDNA (3) to form a nucleo-
protein filament that mediates homologous
pairing (4) followed by strand extension (5),
exchange, and repair (6). Putative functions
of BRCA2 are highlighted in the gray circles.
In this model, phosphorylation by DNA dam-
age-signaling kinases such as ATM or ATR
triggers transition of an inactive BRCA2-
RAD51 (purple-green) complex to an active
complex at the site of damage. At later stages
in HR, dephosphorylation may permit the re-
moval of RAD51 from nucleoprotein filaments
by BRCA2 binding. Thus, there may be cy-
cling between active and inactive states local
to sites of repair. The stoichiometry of
BRCA2-RAD51 binding shown here is not
meant to be literal.
cessing or replication arrest (Figure 3), consistent with ered to the nucleus? What fraction of the nuclear
BRCA2-RAD51 pool transits from the inactive to thethe defects in damage-induced localization of RAD51
that occur after BRCA2 disruption (Yuan et al., 1999; Yu active state following DNA damage? How (and how fast)
can the transition be reversed?et al., 2000). If this view is correct, the nature of BRCA2-
RAD51 binding must change fundamentally in the active A direct role of BRCA2 in the control of RAD51 may
explain why both SSA and NHEJ (RAD51-independentstate such that nucleoprotein filament formation is no
longer suppressed. It is curious in this regard that the processes) are used in BRCA2-deficient cells to repair
site-specific DSBs (Tutt et al., 2001). In BRCA1-deficientspacing between the eight BRC repeat motifs in BRCA2
is conserved from mammals to birds, suggestive, per- cells, however, SSA and HR appear to be decreased,
and NHEJ predominates as the mechanism for repairhaps, of a role in the nucleation of RAD51 filament forma-
tion along stretches of ssDNA. Does the shift from inac- (Moynahan et al., 1999). In either scenario, misdirection
of DSB repair through error-prone SSA or NHEJ, insteadtive to active states involve the “opening up” of a
previously constrained BRCA2 structure, with a corre- of error-free HR, could account for chromosomal insta-
bility through GCR formation at the sites of spontaneoussponding change in function from RAD51 sequestration
to RAD51 nucleation? or induced DSBs.
That BRC repeat peptides can dissolve preformed
RAD51 nucleoprotein filaments (Davies et al., 2001) pro- BRCA1 Links DNA Damage Sensing
to Biological Responsesvokes speculation about a possible role in the removal
of RAD51 from DNA at later stages in the repair process. In what way does BRCA1 participate in pathways for
DSB repair? BRCA1 is also required for efficient HR, butIf phosphorylation serves as a trigger to activate BRCA2-
RAD51 for nucleoprotein filament formation, dephos- far less is known about how it may work in this reaction.
Direct control of RAD51 activity seems unlikely (althoughphorylation might suffice to reverse the transition, such
that there is cycling between active and inactive states the recent discovery that BRCA1 is part of an active
ubiquitin ligase enzyme [see later in the review] may inlocal to sites of repair (Figure 3).
Quantitative considerations raise significant, unan- time alter this stance), because the reported BRCA1-
RAD51 complex contains no more than 2%–5% of theswered questions about these ideas. Given the lower
expression of BRCA2 relative to RAD51, how can all (or cellular content of each molecule (Scully et al., 1997b)
and is not represented amongst the major BRCA1 poolseven most?) nuclear RAD51 remain sequestered in an
undamaged cell? Must the proteins come together prior that can be fractionated biochemically from cells (Wang
et al., 2000).to nuclear entry, such that only inactive RAD51 is deliv-
Review
175
Figure 4. Putative Roles of BRCA1 Based on Reported Interactions
Protein-protein interactions that may mediate particular functions are marked, but the diagrams themselves are naive outlines of a complex
(but currently uncertain) regulatory circuitry, and are for illustration only. BRCA1 works as a signal processor (1) during DNA damage responses
in complex with proteins that bind to aberrant DNA structures (sensors), and the kinases that signal their presence. Phosphorylation of BRCA1
may be essential for local functions [control of DSB resection (2), altering DNA topology (3)] near a DNA lesion, as well as for distant functions
such as transcriptional control of checkpoint genes (4) (e.g., GADD45) or targets of estrogen receptor signalling (see Note Added in Proof),
or transcription-coupled DNA repair (5). BRCA1 works with BARD1 (6) as a ubiquitin ligase of unknown specificity—this interaction is not
dependent on DNA damage and has far-reaching implications for function (see text). These roles need not be mutually exclusive, and will
probably involve distinct intracellular pools or modification (by phosphorylation?) of BRCA1 (see text).
Local Activities of BRCA1 at Sites of DNA Damage role for BRCA1 in its generation may be important when
directing DSB repair down these routes. Indeed, HR andEvidence is mounting that BRCA1 plays a more proximal
and extensive role in the cellular response to DSBs (Fig- SSA are defective (but NHEJ is unaffected) in BRCA1-
deficient cells.ure 4). Sites of DNA damage are marked within minutes
by the phosphorylation of a histone species, H2A-X, BRCA1 may also have local activities at DSB sites
through its interaction with enzymes that alter chromatinwhich spreads over a region spanning thousands of
bases around the lesion, suggesting that chromatin re- and DNA structure. BRCA1 interacts with SWI/SNF (Bo-
char et al., 2000) or other proteins (Ye et al., 2001) thatmodeling may occur to facilitate access of the repair
machinery. BRCA1 is an early migrant to sites of H2A-X remodel chromatin, with regulators of histone acetyla-
tion/deacetylation (Pao et al., 2000; Yarden and Brody,phosphorylation (Paull et al., 2000), consistent with a
role in the events that follow at the site of breakage. 1999), and with DNA helicases, including the RecQ ho-
molog encoded by the Bloom’s syndrome gene, BLMSeveral protein-protein interactions of BRCA1 seem
relevant in this light. BRCA1 interacts with the MRE11/ (Wang et al., 2000), and the novel helicase BACH1 (Can-
tor et al., 2001). How these interactions may assist DSBRAD50/Nbs1 protein complex (Zhong et al., 1999; Wang
et al., 2000), containing the mammalian homologs of repair is currently speculative. Chromatin changes medi-
ated in part by histone modification could make DNAyeast molecules known to participate in DSB repair,
comigrants to sites marked by phospho-H2A-X. Recent surrounding a break more accessible to the repair ma-
chinery, as could the recruitment of helicase activities.data suggests that the interaction is functional. MRE11
encodes a nuclease activity, which resects flush DSB DNA Damage Sensing and Checkpoint Control
of the Cell Cycleends to generate ssDNA tracts (Figure 4). Under certain
in vitro conditions, BRCA1 can inhibit this activity of BRCA1 is rapidly phosphorylated after DNA damage in
dividing cells, suggesting that it may work downstreamMRE11 (Paull et al., 2001), regulating the length and
presumably the persistence of ssDNA generation at of the checkpoint mechanisms that sense and signal
DNA damage or problems with DNA replication, during Ssites of DNA breakage. ssDNA is a substrate for repair
by the HR and SSA mechanisms, and conceivably, a phase. In yeast, a group of four protein kinases (RAD3p/
Cell
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MEC1, TEL1p, CHK1p, and CDS1p/RAD53p) are essen- A key prediction from this model is that the differential
phosphorylation of BRCA1, already reported in re-tial—and proximal—components of these mechanisms.
There is now good evidence that BRCA1 is phosphory- sponse to different DNA damaging agents, will affect
in a specific way its interaction with different effectorlated by the mammalian homologs of at least three ki-
nases in this group and that the modifications contribute pathways. Direct experimental evidence to support this
idea is currently limited, and available information sug-to its function. The kinases include ATM (the RAD3p/
TEL1p homolog mutated in the human disease ataxia gests it will not be easy to come by. The tumor suppres-
sor p53 (like BRCA1, a protein to which a long list oftelangiectasia), the ATM-related MEC1p homolog ATR,
and CHK2, homologous to CDS1p/RAD53p. Interest- functions in DNA damage responses has been ascribed)
is a case in point. p53, too, undergoes complex patternsingly, patients with ataxia telangiectasia are susceptible
to cancer, and cells deficient in ATM or ATR exhibit a of phosphorylation by checkpoint kinases that are pre-
dicted to alter downstream functions; but many yearsprogressive impediment to cell proliferation and sponta-
neous chromosomal instability, as do BRCA-deficient after its description, the biological meaning of p53 phos-
phorylation is yet to be precisely specified.cells, hinting that the biological functions of these ki-
nases may in part be mediated through BRCA phosphor- The likely complexities of the role played by BRCA1
in connecting DNA damage-sensing and responseylation.
BRCA1 as a Signal Processor for DNA mechanisms are well illustrated by its function in regulat-
ing the expression of GADD45 (Harkin et al., 1999; Li etDamage Responses
Phosphorylation of BRCA1 (Cortez et al., 1999; Lee et al., 2000; Zheng et al., 2000), a tumor suppressor gene
that is also a downstream target of the p53 pathway.al., 2000; Tibbetts et al., 2000) by each of these kinases
is activated by distinct stimuli and is targeted to distinct GADD45 transcription is normally suppressed by a core-
pressor complex in which BRCA1 associates with theclusters of serine residues, suggesting that it will serve
a distinct purpose in each instance. The chemical nature novel KRAB domain transcription factor ZBRK1. After
ionizing irradiation, phosphorylation of BRCA1 by ATMof the initiating DNA lesion is an important influence, with
differences apparent among ionizing radiation (which relieves GADD45 repression (although the mechanism
by which this may be accomplished is contested [Wu-primarily induces DNA breakage), UV light (nucleotide
lesions), or replication arrest induced by hydroxyurea Baer and Baer, 2001] and remains unclear). In this way,
BRCA1 processes signals through ATM to achieve tran-(strand gaps). Thus, ATM and CHK2 phosphorylate
BRCA1 after ionizing radiation, whereas ATR is more scriptional regulation of GADD45 in response to DSBs;
however, the specificity of this response and its molecu-specifically activated after UV treatment or replication
arrest. lar mechanism remain elusive.
One functional consequence is in the checkpoint con-
trol of cell cycle progression. BRCA1 has been impli- Upstream and Downstream in DNA Damage
cated in several different checkpoint events (Xu et al., Responses, Where Is BRCA1?
2001a). When exposed to ionizing radiation, BRCA1- The portrait presented here gives BRCA1 both upstream
deficient cells fail to arrest scheduled DNA synthesis in and downstream roles in the response to DNA damage
(Figure 4). On the one hand, BRCA1 participates in pro-S phase, a feature also characteristic of ATM deficiency.
The G2 arrest induced by radiation requires BRCA1, tein complexes that apparently have functions intrinsic
to the sensing and signaling of different types of DNAwhich must be phosphorylated by ATM for this response
to occur. The S and G2 checkpoints are probably acti- lesions. On the other, it works as a sequence-specific
transcriptional regulator of genes whose expression af-vated by DNA breakage, but another checkpoint re-
sponse mediated by BRCA1, which is postulated to fects checkpoint enforcement and other downstream
biological responses. Such diverse functions, while diffi-monitor the degree of chromatid decatenation as cells
progress from G2 to M, is unresponsive to DNA break- cult to accommodate in one austere model without se-
lectively ignoring particular swathes of experimentalage—and independent of ATM (Deming et al., 2001).
Thus, the scenario that emerges is one where BRCA1 data, are nonetheless not mutually exclusive.
This wider “take” on BRCA1 function does highlightworks in multiple pathways that signal cell cycle delays
in the presence of different kinds of DNA lesions (Figure gaps in current knowledge. Notable amongst these is
the incomplete information concerning the whereabouts4). Consistent with this idea, BRCA1 cohabits in high-
molecular-weight complexes with many different pro- of BRCA1 during division and after DNA damage, or
replication arrest. The focal localization of BRCA1 inteins that bind to abnormal DNA structures, as well as
with the checkpoint kinases that activate downstream nuclear “dots” during S and G2 probably reflects only
a fraction of the cellular pool, perhaps that which isresponses (Wang et al., 2000). Complex formation very
probably changes dynamically during cell cycle and bound to particular nuclear structures. Visible BRCA1
foci that appear after DNA damage (some of which alsoafter different kinds of DNA damage: different multipro-
tein complexes may be created and dismantled in re- contain BRCA2 and RAD51) are likely to represent ag-
gregates of hundreds or more molecules. They do notsponse to different stimuli. BRCA1’s precise role here
remains to be clarified. It is attractive to posit, however, coincide (Paull et al., 2000) in timing or number with the
predicted kinetics of DSB repair, or with the expectedthat it works as a signal “processor” to coordinate DNA
damage-sensing mechanisms with appropriate biologi- number of broken DNA ends. For all these reasons,
available data probably provide only a narrow view ofcal responses. From this viewpoint, it is easy to see how
distinct patterns of BRCA1 phosphorylation by different where BRCA1 is, or what it is doing. These caveats also
apply, by and large, to BRCA2, and similarly restrictkinases could reflect the circumstances of sensing, and
in turn, could dictate the pattern of response. exposition of its function.
Review
177
BRCA2 in Cell Cycle Control? nisms for replication restart are frequently used during
normal cell division, even where there is no exogenouslyIt is not known if BRCA2 is a target of S and G2 check-
point kinases, but aspects of its behavior are changed induced DNA damage. For example, in recombination-
defective E. coli RecBCD or RecARecD mutants, irre-when dividing cells undergo replication arrest or re-
spond to DNA damage (Chen et al., 1998b), and there versibly stalled forks break down into unrepaired DSBs
(Michel et al., 1997; Seigneur et al., 1998), which sponta-is reason to believe that the changes can be brought
about by phosphorylation. Whether or not BRCA2 par- neously accumulate to high levels even during normal
growth. Moreover, there is limited but provocative evi-ticipates directly in cell cycle regulation or checkpoint
function is more vexed. Where tested, checkpoint func- dence that homologous recombination is stimulated by,
and necessary for, normal DNA replication in simpletion is remarkably well preserved in BRCA2-deficient
primary cells (Patel et al., 1998). It has been suggested eukaryotes. When the progress of replication forks
through the yeast ribosomal DNA genes is visualized bythat BRCA2 participates in G2/M control through its
interaction with a novel protein, BRAF35, which prefer- two-dimensional gel electrophoresis, X shaped Holliday
junction structures are found to accumulate cyclicallyentially binds in vitro to branched DNA structures
(Marmorstein et al., 2001). BRAF35 and BRCA2 colocal- during normal S phase (Zou and Rothstein, 1997). These
structures typically represent the crossovers betweenize to condensing chromosomes, and the microinjection
of antibodies against either molecule delays metaphase DNA strands undergoing recombination; thus, their for-
mation in replicating loci links recombination to normalprogression. It is not straightforward to conclude from
these observations that BRCA2 directly regulates mi- DNA replication.
The behavior of cells deficient in BRCA proteins intotic progression. For instance, because BRCA2 is es-
sential for DNA repair, its dysfunction is predicted to some respects can be related to the paradigms devel-
oped in simpler organisms. BRCA-deficient cells suffercause the appearance of unrepaired DNA lesions, which
could signal cell cycle delays through the activation a progressive impediment to cell division that worsens
with repeated rounds of division in culture (Patel et al.,of the known checkpoints that monitor DNA structure,
indirectly delaying metaphase progression. Similar ca- 1998; Xu et al., 1999a), reminiscent of the growth of
bacterial mutants deficient in recombination. Chromo-veats apply to interpreting the centrosome amplification
that occurs in BRCA2- (or BRCA1-) deficient cells (Tutt somal aberrations accumulate the more often BRCA-
deficient cells divide, the frequent occurrence of breakset al., 1999; Xu et al., 1999a) as being reflective of a role
in mitotic control. It is clear that BRCA-deficient cells affecting a single chromatid being consistent with failure
to reactivate a replication fork stalled at a gap in theare slow to progress through S phase (see later in this
review). These delays could—by prolonging the activity template. BRCA2-deficient cells spontaneously accrue
DNA strand breaks during growth (Yu et al., 2000), justof cyclin/cdk complexes operational during S phase (re-
viewed in Nigg, 2001)—be an indirect cause. Thus, it is as do bacterial RecA pathway mutants, again suggestive
of an inability to reactivate stalled replication.difficult to distinguish between the chicken and the egg,
and more work will be needed before it becomes clear Replication in mammalian cells undoubtedly pro-
ceeds in a more complex milieu than in bacteria or yeast,whether or not BRCA2 is a regulator of cell cycle events,
independent of its role in DNA repair. and the high level of cooperativity between replication
and recombination implicit in this model cannot yet be
explained in molecular terms. Although this needs muchFixing Stalled Replication Forks
further investigation, some of the protein-protein inter-Why should chromosomal instability occur spontane-
actions of BRCA proteins suggest their involvement.ously during the division of BRCA-deficient cells? Both
After hydroxyurea treatment, which stalls replication andBRCA1 and BRCA2 are essential for homologous re-
induces recombination between sister chromatids,combination, and one appealing explanation stems from
BRCA1 redistributes into discrete nuclear sites (Scullythe notion that an important biological function of re-
et al., 1997a; Zhong et al., 1999; Wang et al., 2000) thatcombination systems is to enable the error-free reactiva-
also contain proteins involved in fixing stalled replicationtion of DNA replication forks stalled at template lesions
(e.g., MRE11/RAD50/Nbs1), in sister chromatid recom-(reviewed in Cox et al., 2000). It has been proposed
bination (e.g., BLM helicase), and in DNA polymerase(Venkitaraman, 2000) that the inability to carry out such
loading (e.g., PCNA, RFC). BRCA2 may also be recruiteda function could explain defects in cell proliferation and
to such sites (Chen et al., 1998b), where its role in RAD51chromosomal structure observed in BRCA2-deficient
control could promote the recombinational events re-cells; aspects of this scheme have also been applied to
quired for replication restart.BRCA1 (Scully and Livingston, 2000; Wang et al., 2000).
Key features of the model come from work on E. coli,
which shows that many DNA lesions encountered by Replication “Housekeeping”
and Cancer Predispositiona replication fork can block its progression, including
strand gaps, ultraviolet light-induced nucleotide dimers, In yeast recombination mutants, replication-associated
DSBs are premutagenic lesions. They may become sub-and base lesions from the spontaneous oxidation or
hydrolysis of DNA. Fork progression in E. coli can be strates for error-prone repair pathways (Chen et al.,
1998a) such as NHEJ or SSA, or they may direct break-reactivated when homologous pairing between the na-
scent DNA strands enables bypass of the lesion, fol- induced replication (reviewed in Kraus et al., 2001), gen-
erating GCRs such as translocations or deletions. Suchlowed by origin-independent reinitiation of the replica-
tion fork from the recombination intermediates. a scenario could plausibly explain characteristics of the
spontaneous chromosomal instability that occurs inThere is good evidence that recombinational mecha-
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BRCA-deficient cells, underpinning their mutability and component proteins, and recent studies suggest a
structural basis for this, that may also be relevant topropensity for neoplastic transformation. However, it
is still not clear if such abnormalities are measurably target specificity (Brzovic et al., 2001). This poorly char-
acterized function of BRCA1 may have far-reaching im-enhanced in cells heterozygous for BRCA mutations.
Studies in murine models have so far revealed no effect plications for its biology. An enzymatic function of this
kind could make interactions involving even a very smallof heterozygosity, but it will be important to address
this issue in human epithelial cells because inheritance BRCA1 pool biologically significant, and because the
conjugation of ubiquitin or ubiquitin-like molecules hasof one defective BRCA allele suffices for cancer predis-
position. profound and variable consequences for the longevity
or activity of substrate proteins, could help to explain
the apparent multiplicity of biological roles ascribed toTranscription, Transcription-Coupled Repair,
BRCA1. Phosphorylation or other inducible changes inand RNA Metabolism
BRCA1 could alter the range of substrate specificities,The contribution made to tumor suppression by other
connecting specific biologic responses to triggeringfunctions ascribed to BRCA1 and BRCA2 is currently
stimuli. Indeed, the central question now pertaining tounclear. Connections with transcription and RNA metab-
these findings relates to the nature of the cellular targetsolism fall into this category. Reference has already been
for the BRCA1/BARD1 complex (Baer, 2001).made, in relation to DNA repair and checkpoint enforce-
One possible connection is already apparent. The pro-ment, to BRCA1’s interactions with proteins that modify
tein encoded by a newly isolated gene FANCD2 mutatedchromatin structure and to its function as a transcription
in Fanconi’s anemia, a disease characterized by chro-regulator, and there is limited evidence that BRCA2 may
mosomal instability and cancer predisposition, localizeswork similarly (Fuks et al., 1998). Moreover, BRCA1 inter-
with BRCA1 to focal sites after DNA damage (Garcia-acts with the RNA polymerase II holoenzyme through a
Higuera et al., 2001). Intriguingly, redistribution is depen-helicase component (Anderson et al., 1998). There is,
dent upon monoubiquitination of FANCD2, although itas yet, no firm evidence that these interactions reflect
is not known if the BRCA1/BARD1 complex can performgeneral roles of BRCA proteins in the control of gene
this modification.expression, whether tissue-specific or otherwise.
BRCA1-deficient cells are defective in transcription-
coupled DNA repair (Gowen et al., 1998; Le Page et Checkpoint Inactivation and the Transformation
al., 2000), a process in which base lesions (following of BRCA-Deficient Cells
oxidative damage, for example) are removed preferen- Paradoxically in relation to their functions as tumor sup-
tially from the transcribed DNA strand. Consistent with pressors, mice deprived of BRCA1 or BRCA2 succumb
this idea, BRCA1 associates with the mismatch repair to early embryonal lethality, accompanied by a severe
proteins MSH2 and MSH6, known mediators of this pro- proliferative defect and signs that p53-dependent cell
cess (Wang et al., 2000). A similar, but less severe, defect cycle arrest has been activated (Ludwig et al., 1997;
has been reported in BRCA2-deficient cells, but protein Sharan et al., 1997; Suzuki et al., 1997). Increased under-
interactions that could contribute to this have not yet standing of the requirement for BRCA1 and BRCA2 in
been reported (Le Page et al., 2000). the maintenance of chromosomal stability makes the
BARD1, a protein which interacts with BRCA1 through basis for these phenotypes more clear, but how do they
the N-terminal RING domain (Figure 1), has been impli- relate to tumor suppression?
cated in the control of RNA processing following DNA If BRCA gene disruption were to occur in an otherwise
damage (Kleiman and Manley, 2001). Normally, nascent normal cell, it seems likely that only a limited window
messenger RNAs must be endonucleolytically cleaved of survival would be possible without the accompanying
at their 3 end prior to polyadenylation: an in vitro assay inactivation of cell cycle checkpoints, which would oth-
for this reaction is found to be strongly but transiently erwise arrest growth in the face of unrepaired DNA dam-
inhibited following DNA damage. Inhibition is dependent age and chromosomal aberrations. The chronology of
upon BARD1 and possibly upon complex formation with events in the cancer-prone tissues of humans who in-
BRCA1 and the polyadenylation factor CstF50 (Kleiman herit BRCA mutations, therefore, becomes significant.
and Manley, 1999, 2001). The mechanism by which inhi- These individuals are heterozygous for the mutations,
bition is brought about is not known, but it is tempting and since heterozygosity is not itself lethal to cells, the
to speculate that the recently identified ubiquitin ligase second event in tumorigenesis may involve checkpoint
activity of the BARD1-BRCA1 heterodimer (see later in gene inactivation rather than loss of the second BRCA
this review) may be involved, targeting for degradation allele. Indeed, a study of the sequence of molecular
the proteins that carry out RNA processing. Interest- events underlying pancreatic cancer progression in
ingly, a cancer-associated BARD1 mutant lacks this BRCA2 heterozygotes lends some support to the idea
function (Kleiman and Manley, 2001), a tentative link that inactivation of the second BRCA allele occurs late
with tumor suppression. (Goggins et al., 2000).
Mouse models have not provided much insight into
this issue, because in this setting, heterozygosity aloneBRCA1/BARD1 Is a Ubiquitin Ligase
It has recently been demonstrated that, like other RING is insufficient for cancer predisposition. Work in these
models (Jonkers et al., 2001; Xu et al., 2001b) does showproteins, the BARD1/BRCA1 complex functions as an
E3 ubiquitin ligase of (as yet) undetermined specificity that coexisting mutations in checkpoint genes such as
p53 can accelerate breast cancer development when(Hashizume et al., 2001; Ruffner et al., 2001). The hetero-
dimer is far more efficient in this activity than are its BRCA1 or BRCA2 is conditionally disrupted in mammary
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epithelium and can promote carcinogenesis when BRCA structure, cell division, and viability, and so a BRCA-
deficient cell must acquire alterations during tumor evo-heterozygous mice are exposed to the genotoxic effects
of ionizing radiation. lution that overcome or at least ameliorate these prob-
lems. In molecular terms, this may force tumor evolutionIs there evidence that p53 mutations are more fre-
quent in cancers from BRCA mutation carriers? This has down a limited set of routes, limiting the genotypic and
phenotypic variability of the end-product. Thus, as pre-been hard to ascertain, because p53 mutations occur
commonly in sporadic as well as familial cancers. A viously discussed, particular mutations in checkpoint
genes probably offer a selective advantage for the trans-recent aggregated analysis (Greenblatt et al., 2001) of
many prior case-control studies concludes not only that formation of BRCA-deficient cells, and their acquisition
may have knock-on effects that further limit diversity.p53 mutations are more frequent in breast cancers that
carry BRCA alterations, but also that the spectrum of Such constraints may also be set through the effects of
BRCA disruption on other biological processes, and notmutations observed is different from sporadic cases.
This latter observation lends substance to the idea that just on chromosome stability or checkpoint control. For
example, there is emerging evidence that wild-typemutations inactivating particular functions of p53 may
be important for the transformation of BRCA-deficient BRCA1 inhibits the downstream effects of estrogen re-
ceptor signaling (Fan et al., 1999). This pathway couldcells. Intriguingly, there is limited evidence that the p53
mutants isolated from BRCA-deficient tumors in mice become constitutively active in BRCA1-deficient cells,
in turn provoking the frequent loss of estrogen receptor(Lee et al., 1999) or humans (Greenblatt et al., 2001)
share some unusual properties. They contain altered expression found in BRCA1-deficient breast tumors.
The observed distinctions between BRCA1- versusresidues in the DNA binding domain of p53 outside the
traditional mutation “hotspots” and exhibit gain-of-func- BRCA2-deficient tumors emphasize that cancer evolu-
tion proceeds down different routes in each group, con-tion activities that may be relevant to transformation.
Not all cancers from BRCA mutation carriers contain sistent with the arguments put forward here that the
BRCA proteins perform distinct functions in overlappingmutant p53, however, suggesting that there will be alter-
native paths to transformation in this setting. Indeed, biological processes. Further characterization of these
differences at the molecular level will undoubtedly assistthe identity of the checkpoints that arrest growth in
BRCA-deficient cells is not fully clear. Besides check- understanding of BRCA protein function, besides tumor-
igenesis. Furthermore, the inference that at least somepoints governed by p53, there is in vitro evidence that
the inactivation of mitotic checkpoints, such as the spin- of the molecular changes within each group will be ste-
reotyped holds out hope for improvements in diagnosisdle assembly checkpoint mediated in mammals by a
protein complex containing the Bub1 and BubR1 ki- and treatment.
nases, is sufficient to overcome growth arrest and pro-
mote the transformation of BRCA2-deficient murine Tissue Specificity of Cancer Predisposition
cells (Lee et al., 1999). Whether mutations affecting this As yet we know of no good reason why cancer predispo-
checkpoint mechanism also occur in human BRCA-defi- sition associated with BRCA gene mutations should
cient tumors has not yet been ascertained. manifest in particular epithelial tissues such as the
breast, ovary, pancreas, or prostate. Several hypothe-
ses may be entertained. BRCA disruption may have tis-Chromosomal Instability Channels
Tumor Evolution sue-specific effects that favor transformation. For in-
stance, it may make breast or ovarian cells moreIn a model where chromosomal instability predisposes
to carcinogenesis, it might be predicted that cancers sensitive to the effects of local mutagens, such as estro-
gen metabolites. But, as mentioned previously, tissue-arising in the setting of BRCA deficiency would be uni-
formly early in onset due to an accelerated mutation specific effects need not be restricted to a “caretaker”
role in genomic stability: BRCA1 is proposed to workrate, but also highly variable in their histopathological
and molecular features, for the same reason. There is as an inhibitor of estrogen receptor signaling (Fan et
al., 1999), and thus, BRCA deficiency may promote cellevidence, however, that this is not so, although studies
on human BRCA-deficient tumors are currently very pre- outgrowth or survival, akin to loss of a “gatekeeper”
function. Tissue-specific transcriptional regulation me-liminary. For instance, human BRCA1- or BRCA2-defi-
cient breast cancers, far from uniform in their histopa- diated in part by homology-dependent chromosome
“imprinting” (Scully and Livingston, 2000) has also beenthology, do share features that distinguish them in a
general way from one another and from sporadic cases invoked in a similar vein. The altered mammary gland
development (Xu et al., 1999b) and hormone respon-(Lakhani et al., 1998), even though these are not clear-
cut enough to enable diagnosis. Immunohistochemi- siveness (Bennett et al., 2000) reported in murine models
of BRCA deficiency could reflect the loss of any suchcally, BRCA1-deficient tumors predominantly fail to ex-
press receptors for estrogen, unlike controls. Micro- tissue-specific function.
Considered from the perspective that heterozygosityarray-based expression profiles comparing a small
sample of BRCA1-deficient or BRCA2-deficient breast for BRCA mutations is sufficient to predispose to cancer,
an alternative hypothesis is that the frequency withcancers with BRCA-wild-type controls show a conser-
vation of patterns, possibly robust enough to be of pre- which loss of the second BRCA allele occurs may effec-
tively be higher in certain tissues, perhaps those likedictive value (Hedenfalk et al., 2001).
Are these findings incompatible with a caretaker role the breast or ovary, in which prolonged proliferative
quiescence (when BRCA gene function may be dispens-for BRCA genes in cancer predisposition? Not necessar-
ily. BRCA disruption causes defects in chromosome able for viability) alternates with periodic bursts of prolif-
Cell
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control of the RAD51 recombination and DNA repair protein. Mol.eration. These conditions may favor the accumulation
Cell 7, 273–282.of cells in which both BRCA alleles have been lost, in
Deming, P.B., Cistulli, C.A., Zhao, H., Graves, P.R., Piwnica-Worms,particular, tissues like the breast and ovary. Having a
H., Paules, R.S., Downes, C.S., and Kaufmann, W.K. (2001). Thelarger pool of mutant cells from which tumors could
human decatenation checkpoint. Proc. Natl. Acad. Sci. USA 98,
eventually evolve may be of particular significance in 12044–12049.
light of the deleterious effects of homozygosity for BRCA Easton, D.F. (1999). How many more breast cancer predisposition
mutations. genes are there? Breast Cancer Res. 1, 14–17.
Whichever of these possibilities has merit (and they Fan, S., Wang, J., Yuan, R., Ma, Y., Meng, Q., Erdos, M.R., Pestell,
are neither exhaustive nor mutually exclusive), it bears R.G., Yuan, F., Auborn, K.J., Goldberg, I.D., and Rosen, E.M. (1999).
BRCA1 inhibition of estrogen receptor signaling in transfected cells.emphasis that very little is known about the role of BRCA
Science 284, 1354–1356.gene products in the biology of epithelial tissues. With-
Fuks, F., Milner, J., and Kouzarides, T. (1998). BRCA2 associatesout better information, it is unlikely that recent progress
with acetyltransferase activity when bound to P/CAF. Oncogene 17,in defining the biological functions of BRCA1 and BRCA2
2531–2534.can be effectively translated into advances in the pre-
Garcia-Higuera, I., Taniguchi, T., Ganesan, S., Meyn, M.S., Timmers,vention or treatment of cancer.
C., Hejna, J., Grompe, M., and D’Andrea, A.D. (2001). Interaction of
the Fanconi anemia proteins and BRCA1 in a common pathway.
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Note Added in Proof
Recent data suggest that BRCA1 inhibits estrogen receptor signal-
ling through multiple mechanisms that include modulation of coacti-
vator expression (Fan, S., Ma, Y.X., Wang, C., Yuan, R., Meng, Q.,
Wang, J., Erdos, M., Goldberg, I.D., Webb, P., Kushner, P.J., et al.
[2002]. p300 modulates the BRCA1 inhibition of estrogen receptor
activity. Cancer Res. 62, 141–151) and recruitment of histone de-
acetylase activity to promoter bound receptors (Zheng, L., Annab,
L.A., Afshari, C.A., Lee, W.H., and Boyer, T.G. [2001]. BRCA1 medi-
ates ligand-independent transcriptional repression of the estrogen
receptor. Proc. Natl. Acad. Sci. USA 98, 9587–9592). Models to
explain the tissue specificity (or estrogen receptor-negativity) of
BRCA1-deficient cancers should be reevaluated in this light.
